2024 Clinical Application Series

Credit is awarded in the calendar year the assessment is completed. AAPP reports continuing credit for ACPE (CPE Monitor) and BCPP Recertification (BPS) within days of successful exam completion.

Target Audience

BCPPs desiring an evidence-based, in-depth review of contemporary issues in psychiatric pharmacy at the specialist level are the intended audience of this recertification activity. This activity is designed for BCPPs who are auditory and visual learners and/or who learn best from hands-on-learning and dialoguing with specialist faculty and colleagues.

Course Requirements

To satisfactorily complete the recertification programming and receive BCPP Recertification and ACPE credit, candidates must meet the following requirements:

  • Register for this course.
  • Complete the pre-test before starting the activity.
  • Review the full content of the activity and reflect upon its teachings.
  • Abide by a confidentiality and honesty statement requiring individual completion of the course.
  • Complete the post-test at the end of the activity no later than the closing activity date.
  • Complete an activity evaluation form.
  • Wait for an official review of exam questions within 4 weeks following the closing date.
  • Receive a passing grade (76%).
  • Partial credit is not provided; your exam score must meet or exceed the cut-off score in order to receive the ACPE and BCP Recertification credit.
  • Learners who do not achieve a passing score on a post-activity assessment may appeal assessment questions and/or take a remediation assessment. View AAPP's Post-Activity Assessment Appeal and Remediation Policy.
  • Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.

Faculty Information

Katharine "Kaz" Joyer Nelson, MD, DFAPA
Tiffany Buckley, PharmD, BCPP, BCPS
Chelsea Di Polito, PharmD, BCPP
Russell Spieth, MEd, PhD
Kristen Ward, PharmD, BCPP
View biographical information
Katharine "Kaz" Joyer Nelson, MD, DFAPA
Associate Professor of Psychiatry and Behavioral Sciences
University of Minnesota Medical School
Minneapolis, MN
Affiliation/Financial Interest: I am a contributing author and review for UpToDate, an online reference for clinical professionals. I receive royalties for this work. I have authored the chapter on Pharmacotherapy for personality disorders. I have reviewed the chapters on Psychotherapy for borderline personality disorder | Psychotherapy for schizotypal personality disorder | Treatment of antisocial personality disorder
Grant/Research Support: Not specifically applicable to this presentation, but I do receive Educational Research Grant funding from the American Board of Psychiatry and Neurology for educational research unrelated to the topic of BPD treatment.
Consultant: I have provided educational consulting for compensation to potential Graduate Medical Education training sites. This work is unrelated to the topic of BPD treatment.
Other Financial or Material Support: ): I receive royalties for a book I co-edited on the topic of Schizophrenia and psychotic-spectrum disorders from Oxford University Press.
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: There is no FDA-approved medication for the treatment of any personality disorder. I will use generic drug names in my presentation and disclose that all discussion of pharmacology is off-label.
 
Tiffany Buckley, PharmD, BCPP, BCPS
Advanced Practice Psychiatric Pharmacist & Graduate Faculty in the MS in Medical Cannabis Science and Therapeutics
University of Maryland School of Pharmacy
Baltimore, MD
Affiliation/Financial Interest: TRB Speaks, LLC – I am the owner and am employee of a public speaking company about cannabis and mental health.
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Cannabis, cannabidiol (Epidiolex)
 
Chelsea Di Polito, PharmD, BCPP
Assistant Director of the Peer Review for Mental Health Drugs Program
University of Maryland School of Pharmacy
Baltimore, MD
No Relevant Financial Relationships to Disclose
 
Russell Spieth, MEd, PhD
Vice President of Adult Behavioral Health and Licensed Clinical Psychologist
The Centers
Cleveland, Ohio
No Relevant Financial Relationships to Disclose
 
Kristen Ward, PharmD, BCPP
Clinical Assistant Professor
University of Michigan College of Pharmacy
Ann Arbor, MI
No Relevant Financial Relationships to Disclose
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: It is possible we will discuss off-label use of medication during case presentations related to pharmacogenetic testing.
 

Learning Objectives

Evidence-based Management of Borderline Personality Disorder
  1. Assess the evidence for treatment options in the management of borderline personality disorder.
  2. Apply strategies to sustain engagement of patients with personality disorders in treatment.
  3. Design a rational treatment plan for patients with borderline personality disorder.
Role of Cannabis and Cannabidiol in the Treatment of Anxiety Disorders
  1. Distinguish between cannabis, hemp, FDA-approved cannabinoids, and synthetic cannabinoids.
  2. Evaluate the role of cannabis and/or cannabidiol in the treatment of anxiety disorders.
  3. Assess the safety of cannabis and/or cannabidiol when used for the treatment of anxiety disorders.
The Good, the Bad, and the Unknown of Psychotropic Stewardship Implementation: A Focus on Antipsychotics
  1. Provide rationale for implementation of a psychiatric pharmacist led psychotropic stewardship program for antipsychotics.
  2. Assess possible barriers to implementing a psychotropic stewardship program for antipsychotics.
  3. Measure the effectiveness of a psychotropic stewardship program for antipsychotics.
Addressing Ambivalence and Non-Adherence to Mental Health Treatment
  1. Identify factors that contribute to ambivalence to mental health treatment, medication non-adherence, and misalignment between patient and provider goals.
  2. Compare interventions that address mental health treatment ambivalence and/or medication adherence.
  3. Recommend strategies to address ambivalence to mental health treatment and non-adherence based on patient-specific factors.
Using Pharmacogenomics to Optimize Mental Health Comprehensive Medication Management
  1. Assess the impact of pharmacogenomic testing on patient outcomes in psychiatry.
  2. Incorporate health literacy considerations in education to patients about mental health pharmacogenomic testing results.
  3. Apply pharmacogenomic results to psychiatric treatment decisions in comprehensive medication management.

Continuing Education Credit and Disclosures

Activity Dates: 04/07/2024 - 10/09/2024
ACPE Contact Hours: 5
ACPE Numbers: 0284-0000-24-015-H01-P (Application), 0284-0000-24-016-H01-P (Application), 0284-0000-24-020-H04-P (Application), 0284-0000-24-022-H99-P (Application), 0284-0000-24-024-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.

ACPEThe American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Pharmacists can obtain 5 hours of ACPE credit and 5 hours of BCPP Recertification credit by successfully completing the online Clinical Application Series examination.

The American Association of Psychiatric Pharmacists is approved as a Professional Development Provider for the Board Certified Psychiatric Pharmacist (BCPP) specialty by the Board of Pharmacy Specialties (BPS). This course is part of a 5 hour BCPP recertification product earned after successful completion of the associated BCPP recertification examination for the full product.
AAPP reports continuing credit for ACPE (CPE Monitor) and BCPP Recertification (BPS) within days of successful exam completion.

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.

View planning committee disclosures

2024 Recertification Editorial Board

Marissa Cullen, PharmD, BCPP
Clinical Pharmacist
UPMC Western Psychiatric Hospital
Pittsburgh, PA
No Relevant Financial Relationships to Disclose
Beth DeJongh, PharmD, BCPS, BCPP
Director of Continuing Professional Development
American Association of Psychiatric Pharmacists
Lincoln, NE
No Relevant Financial Relationships to Disclose
Alisha D. Donat, PharmD, BCPP
Clinical Pharmacy Specialist - Mental Health
South Texas Veterans Health Care System
San Antonio , TX
No Relevant Financial Relationships to Disclose
Bennett J. Doughty, PharmD, BCPP, BCPS
Clinical Assistant Professor
Binghamton University School of Pharmacy and Pharmaceutical Sciences
Binghamton, NY
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: PsychU- Speaker's Bureau
Traci M. Dutton, PharmD, BCPP, BCPS
Clinical Pharmacy Specialist - Mental Health; Program Director - PGY2 Psychiatric Pharmacy Residency
VA Tennessee Valley Healthcare System
Murfreesboro, TN
Employment: Tennessee Valley VA Healthcare System, Clinical Pharmacy Specialist - Mental Health, Member of VA PBM Educational Advisory Committee which
oversees Board Certification Study Groups
Megan J. Ehret, PharmD, MS, BCPP
BCPP Program Director
Professor
University of Maryland
Baltimore, MD
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Saladex Biomedical Consultant, Lexi-Comp Consultant/Reviewer, SMI Adviser; Pharmacist Consultant
Educational Grants, Research Grants or Contracts: FDA/University of Maryland CERSI, Maryland Behavioral Health Department, NIH
Abigail Hampton, PharmD, BCPP
Clinical Pharmacy Practitioner- mental health
Kansas City Veterans Affairs
Kansas City, MO
No Relevant Financial Relationships to Disclose
Jordan Haygood, PharmD, BCPP
Clinical Pharmacy Specialist - Psychiatry
Medical University of South Carolina
Charleston, SC
No Relevant Financial Relationships to Disclose
Courtney A. Iuppa, PharmD, BCPP
Clinical Pharmacy Manager & Residency Program Director
Center for Behavioral Medicine
Kansas City, MO
No Relevant Financial Relationships to Disclose
Archana R. Jhawar, PharmD, BCPP
Clinical Pharmacist
Jesse Brown VAMC/ UIC College of Pharmacy
Chicago, IL
No Relevant Financial Relationships to Disclose
Dongmi Kim, PharmD, BCPP, BCPS
Assistant Clinical Professor
Fairleigh Dickinson University School of Pharmacy
Florham Park, NJ
No Relevant Financial Relationships to Disclose
Jamie C. Kneebusch, PharmD, BCPP, BCPS
Assistant Clinical Faculty
UC San Diego, Skaggs School of Pharmacy
La Jolla, CA
No Relevant Financial Relationships to Disclose
Linda D. Logan, PharmD, BCACP, BCPP, BCPS
Public Service Associate
University of Georgia
Athens, GA
Educational Grants, Research Grants or Contracts: HRSA Graduate Psychology Education Grant, UGA Mental Health Seed Grants for MHFA and Virtual Dementia Tour, UGA College Pharmacy Ansel Fund
Megan Maroney, PharmD, BCPP
Clinical Associate Professor
Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey
Long Branch, NJ
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Pharmacy Times - speaker and medical writing honoraria, Otsuka Pharmaceuticals - Excel Speakers
Bureau (former, through March 2022), Novus Medical Education - consultant/medical writing, Boehringer Ingelheim - advisory board, Sunovion Pharmaceuticals –
consultant/advisory board, Biogen and Sage Therapeutics - advisory board
Monica Mathys, PharmD, BCGP, BCPP
Professor
Texas Tech University School of Pharmacy
Dallas, TX
Non-Financial Interests: AAPP Foundation Board member
Jessica L. Mulhollan, PharmD, BCPP
Clinical Pharmacy Specialist, Substance Use Disorders and Mental Health Clinical Pharmacy Supervisor
Louis Stokes Cleveland VA Medical Center
Cleveland, OH
No Relevant Financial Relationships to Disclose
Kristen Neumeister, PharmD, BCPP
Clinical Pharmacist
North Texas State Hospital
Fort Worth, TX
No Relevant Financial Relationships to Disclose
Megan O'Connell, PharmD, BCPP
Clinical Pharmacy Specialist - Psychiatry and Neurology
Michigan Medicine
Ann Arbor, MI
No Relevant Financial Relationships to Disclose
Melissa C. Palmer, PharmD, BCPP, BCPS
Clinical Pharmacy Specialist - Mental Health
Alaska VA Healthcare System
Anchorage, AK
No Relevant Financial Relationships to Disclose
Brittany L. Parmentier, PharmD, MPH, BCPS, BCPP
Clinical Pharmacy Specialist in Psychiatry
The Harris Center for Mental Health and IDD
Houston, TX
No Relevant Financial Relationships to Disclose
Jake R. Peters, PharmD, BCPP, BCPS
Assistant Professor of Pharmacy Practice/Clinical Pharmacy Specialist - Psychiatry
Butler University College of Pharmacy/Indiana University Health
Indianapolis, IN
No Relevant Financial Relationships to Disclose
Sarah J. Popish, PharmD, BCPP
VA PBM Academic Detailing Services, Program Manager
Department of Veterans Affairs
Sarasota, FL
No Relevant Financial Relationships to Disclose
Kara R. Wong, PharmD, BCPP
Recertification Editorial Board Chair
Clinical Pharmacist Practitioner, Mental Health
Minneapolis VA Health Care System
Minneapolis, MN
No Relevant Financial Relationships to Disclose

All relevant relationships have been mitigated.

View disclaimer and disclosure of off-label use

Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: There is no FDA approved pharmacological treatment of Borderline Personality Disorder. All pharmacology discussion will be off-label. Generic terminology will be used whenever possible. Discussion of medication class (rather than mentioning an individual medication) will also be used when appropriate. This presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Cannabis, Cannabidiol (Epidiolex). This presentation will include brand names for some products to reduce confusion. My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Pharmacogenetic test results that are not mentioned in product labeling

This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.

In accordance with the Food and Drug Administration (FDA), it is disclosed that there is the potential for discussions concerning off-label uses of a commercial product/devices during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose significant relationships (and any known relationships of their spouse/partner) with commercial companies whose products or services are discussed in this activity. Significant relationships include receiving from a commercial company research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

View fair balance and integrity statement

It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.